Jihong Chen

2.8k total citations · 1 hit paper
60 papers, 1.5k citations indexed

About

Jihong Chen is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Jihong Chen has authored 60 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Jihong Chen's work include Amyloidosis: Diagnosis, Treatment, Outcomes (11 papers), Advanced biosensing and bioanalysis techniques (4 papers) and RNA modifications and cancer (3 papers). Jihong Chen is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (11 papers), Advanced biosensing and bioanalysis techniques (4 papers) and RNA modifications and cancer (3 papers). Jihong Chen collaborates with scholars based in China, United States and France. Jihong Chen's co-authors include David Adams, Jared Gollob, Ole B. Suhr, Arnt V. Kristen, Verena Karsten, John L. Berk, Joshua R. Vest, Teresa Coelho, Alejandra González‐Duarte and Giampaolo Merlini and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jihong Chen

55 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

2019 316 citations Scott D. Solomon, David Adams et al. Circulation profile →

Peers

Countries citing papers authored by Jihong Chen

Since Specialization

Citations

This map shows the geographic impact of Jihong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jihong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jihong Chen more than expected).

Fields of papers citing papers by Jihong Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jihong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jihong Chen. The network helps show where Jihong Chen may publish in the future.

Co-authorship network of co-authors of Jihong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Jihong Chen. A scholar is included among the top collaborators of Jihong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jihong Chen. Jihong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Highly sensitive electrochemiluminescence biosensor for miRNA-21 based on cascaded signal amplification and magnetic separation 2025 ·Microchemical Journal ·(unknown), (unknown), Yunpeng Xu, (unknown), Yanzi Zhang, (unknown), Zhenyu Lin, Jihong Chen	0
2	Renal-Clearable Biomass-Derived Carbon Dots with Red Fluorescence for Masked Cryptic Kidney Injury Imaging 2025 ·ACS Applied Bio Materials ·(unknown), Yuanyuan Wang, (unknown), (unknown), Jinxin Zhang, Yaodong Huang, Yongfan Men, Pengfei Zhang, Jihong Chen	3
3	Unraveling m6A RNA methylation: From epitranscriptomics to therapeutic frontiers in renal cell carcinoma 2025 ·Cellular Signalling ·(unknown), Jiahui Chen, (unknown), (unknown), Yunpeng Xu, (unknown), Yanzi Zhang, Jihong Chen	0
4	Protein kinase ROCK1 activates mitochondrial fission linking to oxidative stress and muscle atrophy 2025 ·Kidney International ·(unknown), Jihong Chen, (unknown), Hongchun Lin, (unknown), Sung Yun Jung, Sandhya S. Thomas, (unknown), Yanlin Wang, (unknown), Zhaoyong Hu	0
5	An ESIPT‐Based Fluorochromogenic Tweezer for Reversible and Portable Detection of Al³⁺ Ions 2025 ·Chemistry - A European Journal ·Daoyong Jiang, (unknown), Yizhao Chen, Xiuwen Zhang, Jihong Chen, Xiaowei Qi, Pengfei Zhang, Yong Wang	1
6	A comprehensive examination and analysis of the effectiveness and safety of finerenone for the treatment of diabetic kidney disease: a systematic review and meta-analysis 2024 ·Frontiers in Endocrinology ·Jianyu Chen, (unknown), Jiahui Chen, (unknown), (unknown), Yanzi Zhang, (unknown), Yunpeng Xu, Jihong Chen	0
7	Oryzanol Attenuates High Fat and Cholesterol Diet-Induced Hyperlipidemia by Regulating the Gut Microbiome and Amino Acid Metabolism 2022 ·Journal of Agricultural and Food Chemistry ·(unknown), Jihong Chen, (unknown), Tianyi Guo, Dandan Qin, Zuomin Hu, (unknown), Yaping Zhou, Otobong Donald Akan, Ji Wang, Feijun Luo, Qinlu Lin	29
8	Oryzanol alleviates high fat and cholesterol diet-induced hypercholesterolemia associated with the modulation of the gut microbiota in hamsters 2022 ·Food & Function ·(unknown), Jihong Chen, (unknown), Tianyi Guo, Dandan Qin, Zuomin Hu, (unknown), Ji Wang, (unknown), Lixin Wen, Feijun Luo, Qinlu Lin	49
9	STUDY DESIGN AND RATIONALE OF HELIOS-B: A PHASE 3 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF VUTRISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY 2020 ·Journal of the American College of Cardiology ·Rebecca A. Shilling, Verena Karsten, Nancy Silliman, Jihong Chen, Wei Li, Joshua R. Vest	11
10	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis breakdown → 2019 ·Circulation ·Scott D. Solomon, David Adams, Arnt V. Kristen, Martha Grogan, Alejandra González‐Duarte, Mathew S. Maurer, Giampaolo Merlini, Thibaud Damy, Michel Slama, Thomas H. Brannagan, Angela Dispenzieri, John L. Berk, Amil M. Shah, Pushkal Garg, Akshay Vaishnaw, Verena Karsten, Jihong Chen, Jared Gollob, Joshua R. Vest, Ole B. Suhr	316
11	Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis 2019 ·Journal of Neurology ·Alejandra González‐Duarte, John L. Berk, Dianna Quan, Michelle L. Mauermann, Hartmut Schmidt, Michael Polydefkis, Márcia Waddington‐Cruz, Mitsuharu Ueda, Isabel Conceição, Arnt V. Kristen, Teresa Coelho, Cécile Cauquil, Céline Tard, (unknown), Emre Aldinc, Jihong Chen, Marianne T. Sweetser, Jing Jing Wang, David Adams	42
12	Neuropathy progression in patients with hATTR amyloidosis : Analysis of the APOLLO placebo arm 2018 ·Journal of the Peripheral Nervous System ·P. James B. Dyck, David Adams, (unknown), Arnt V. Kristen, Alejandra González‐Duarte, John L. Berk, (unknown), Jared Gollob, (unknown), Jihong Chen, Ole B. Suhr	0
13	Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO Study (S31.003) 2018 ·Neurology ·David Adams, Alejandra González‐Duarte, William O’Riordan, Chih‐Chao Yang, Taro Yamashita, Arnt V. Kristen, (unknown), Hartmut Schmidt, Teresa Coelho, John L. Berk, (unknown), P. James B. Dyck, Pritesh J. Gandhi, Marianne T. Sweetser, Jihong Chen, Sunita Goyal, Jared Gollob, Ole B. Suhr	1
14	Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (S27.004) 2017 ·Neurology ·David Adams, Teresa Coelho, Isabel Conceição, Márcia Waddington‐Cruz, Hartmut Schmidt, Juan Buades, Josep M. Campistol, Jean Pouget, John L. Berk, Michael Polydefkis, (unknown), (unknown), Jihong Chen, Jared Gollob, Ole B. Suhr	10
15	Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy 2017 ·BMC Neurology ·David Adams, Ole B. Suhr, P. James B. Dyck, William J. Litchy, (unknown), Jihong Chen, Jared Gollob, Teresa Coelho	130
16	Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer 2017 ·British Journal of Cancer ·Tudor–Eliade Ciuleanu, Samreen Ahmed, Joo-Hang Kim, J. Mezger, Keunchil Park, Michael Thomas, Jihong Chen, Srinivasu Poondru, (unknown), (unknown), Fiona Blackhall	28
17	Metabonomics study of the acute graft rejection in rat renal transplantation using reversed-phase liquid chromatography and hydrophilic interaction chromatography coupled with mass spectrometry 2012 ·Molecular BioSystems ·Jihong Chen, Hao Wen, Jian Liu, (unknown), Xinjie Zhao, Xianzhe Shi, Guowang Xu	19
18	On-line hemodiafiltration to correct calcium and phosphate metabolic disorder in uremia hemodialysis patients 2012 ·Jihong Chen	1
19	Effect of continuous venovenous haemodiafiltration on the clearances of various solutes in multiple organ dysfunction syndrome dogs 2011 ·Jihong Chen, (unknown), (unknown)	1
20	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure 2011 ·European Journal of Cancer ·Nizar M. Tannir, (unknown), Christian Kollmannsberger, Marc S. Ernstoff, David J. Perry, Leonard J. Appleman, Edwin M. Posadas, Daniel Cho, Toni K. Choueiri, A. Coates, Neeraj Gupta, Rajendra Pradhan, Jiang Qian, Jihong Chen, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson, M. Dror Michaelson	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact